Canine Da2Ppv+Cv Alu Adj Lv+Kv

Verify with FDA CVM →

22 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
22
Total Reports
5
Deaths Reported
2270.0%
Death Rate

Active Ingredients

Canine Da2Ppv+Cv Alu Adj Lv+Kv

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 22

Most Affected Breeds

Shih Tzu 3
Rottweiler 3
Mountain Dog - Bernese 3
Bulldog 3
Terrier (unspecified) 2
Doberman Pinscher 2
Terrier - Yorkshire 1
Bulldog - French 1
Crossbred Canine/dog 1
Maltese 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 7
Vomiting 6
Diarrhoea 5
Anorexia 4
Death 4
Lack of efficacy - NOS 3
Other abnormal test result NOS 3
Lack of efficacy (virus) - NOS 3
Unable to stand 2
Ataxia 2
Emesis 2
Pale mucous membrane 2

Outcome Breakdown

Recovered/Normal
10 (37.0%)
Ongoing
7 (25.9%)
Outcome Unknown
5 (18.5%)
Died
5 (18.5%)

Data Summary

Metric Value
Total adverse event reports 22
Reports involving death 5
Case-fatality rate (reported events) 2270.0%
Distinct species in reports 1
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Canine Da2Ppv+Cv Alu Adj Lv+Kv Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 22 adverse event reports referencing Canine Da2Ppv+Cv Alu Adj Lv+Kv, including 5 reports in which the animal died — a 2270.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Canine Da2Ppv+Cv Alu Adj Lv+Kv. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Canine Da2Ppv+Cv Alu Adj Lv+Kv reports are Dog (22 reports), with Dog accounting for the largest share. Within those species, Shih Tzu (3), Rottweiler (3), Mountain Dog - Bernese (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Canine Da2Ppv+Cv Alu Adj Lv+Kv are Lethargy (see also Central nervous system depression in 'Neurological') (7), Vomiting (6), Diarrhoea (5), Anorexia (4). Of the 27 reports with a coded outcome, Recovered/Normal is the leading category at 37.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Canine Da2Ppv+Cv Alu Adj Lv+Kv.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial